Advinus Therapeutics Ltd - Product Pipeline Review - 2016

Published: Jun, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Advinus Therapeutics Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Advinus Therapeutics Ltd - Product Pipeline Review - 2016', provides an overview of the Advinus Therapeutics Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Advinus Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Advinus Therapeutics Ltd
- The report provides overview of Advinus Therapeutics Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Advinus Therapeutics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Advinus Therapeutics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Advinus Therapeutics Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Advinus Therapeutics Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Advinus Therapeutics Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Advinus Therapeutics Ltd Snapshot 6
Advinus Therapeutics Ltd Overview 6
Key Information 6
Key Facts 6
Advinus Therapeutics Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Advinus Therapeutics Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Advinus Therapeutics Ltd - Pipeline Products Glance 14
Advinus Therapeutics Ltd - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Advinus Therapeutics Ltd - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Advinus Therapeutics Ltd - Drug Profiles 17
GKM-001 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule for Type 2 Diabetes 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PNQ-103 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PNQ-201 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
PNQ-370 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PNQ-849 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule for Visceral Leishmaniasis 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PNQ-154 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PNQ-401 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PNQ-701 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Leishmaniasis 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule to Antagonize GPR40 for Obesity 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Advinus Therapeutics Ltd - Pipeline Analysis 34
Advinus Therapeutics Ltd - Pipeline Products by Target 34
Advinus Therapeutics Ltd - Pipeline Products by Route of Administration 35
Advinus Therapeutics Ltd - Pipeline Products by Molecule Type 36
Advinus Therapeutics Ltd - Pipeline Products by Mechanism of Action 37
Advinus Therapeutics Ltd - Recent Pipeline Updates 38
Advinus Therapeutics Ltd - Dormant Projects 39
Advinus Therapeutics Ltd - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Advinus Therapeutics Ltd, Key Information 6
Advinus Therapeutics Ltd, Key Facts 6
Advinus Therapeutics Ltd - Pipeline by Indication, 2016 8
Advinus Therapeutics Ltd - Pipeline by Stage of Development, 2016 10
Advinus Therapeutics Ltd - Monotherapy Products in Pipeline, 2016 11
Advinus Therapeutics Ltd - Partnered Products in Pipeline, 2016 12
Advinus Therapeutics Ltd - Partnered Products/ Combination Treatment Modalities, 2016 13
Advinus Therapeutics Ltd - Phase II, 2016 14
Advinus Therapeutics Ltd - Preclinical, 2016 15
Advinus Therapeutics Ltd - Discovery, 2016 16
Advinus Therapeutics Ltd - Pipeline by Target, 2016 34
Advinus Therapeutics Ltd - Pipeline by Route of Administration, 2016 35
Advinus Therapeutics Ltd - Pipeline by Molecule Type, 2016 36
Advinus Therapeutics Ltd - Pipeline Products by Mechanism of Action, 2016 37
Advinus Therapeutics Ltd - Recent Pipeline Updates, 2016 38
Advinus Therapeutics Ltd - Dormant Developmental Projects,2016 39
Advinus Therapeutics Ltd, Other Locations 40